Structural Heart Procedures Market Overview

Valued at USD 13.20 billion in 2025, the structural heart procedures market is projected to reach USD 14.34 billion in 2026 and USD 28.02 billion by 2034, growing at a CAGR of 8.72% during the forecast period 2026–2034. Key players include Abbott Laboratories; Artivion; Boston Scientific; Edwards Lifesciences; JenaValve Technology; Johnson & Johnson MedTech; LivaNova; Medtronic; Meril Life Sciences; MicroPort Scientific; Peijia Medical; and Venus Medtech.

TAVR Dominates the Procedure Segment

By procedure, the market is segmented into TAVR, TMVR, LAAC, and others. TAVR held nearly 62.40% share in 2025, making it the dominant procedure. In October 2025, Medtronic launched the Stedi Extra Support Guidewire for its TAVR systems, and in February 2026 Medanta Noida launched its structural heart programme after completing its first three TAVI procedures. These developments show continued investment in both device ecosystems and clinical programs.

TMVR Is the Highest-Growth Procedure

TMVR is the highest-growth procedure segment, with a CAGR of around 13.20%, well above the market's 8.72% CAGR. In December 2025, Edwards Lifesciences received FDA clearance for SAPIEN M3, a transseptal transcatheter mitral valve replacement for severe mitral regurgitation patients ineligible for surgery. In November 2025, Philips introduced an AI-based imaging system to improve transcatheter mitral valve repair. LAAC is also covered in the procedure segmentation alongside other procedures.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/structural-heart-procedures-market

Aortic Stenosis and Tricuspid Regurgitation

By indication, aortic stenosis was dominant in 2025, while tricuspid regurgitation is the highest-growth indication, with a CAGR of nearly 12.80%. Other indications covered include mitral regurgitation, congenital heart defects, and atrial fibrillation. The contrast between a dominant established indication and a faster-growing newer one suggests that industry attention is expanding beyond the aortic valve.

Disease Burden Supports Demand

The report cites American Heart Association 2021 global figures showing 54.8 million cases of rheumatic heart disease, 13.3 million of calcific aortic valve disease, and 15.5 million of degenerative mitral valve disease. In the EU, the OECD reports that cardiovascular disease causes one in three deaths, with 1.7 million deaths in 2022, affecting around 62 million people. These figures illustrate the clinical need that structural heart interventions address.

Regional Context

North America was the largest region in 2025 with nearly 41.60% share, while Asia Pacific is expected to have the highest CAGR, with China, India, Japan, and South Korea named as key countries. Europe holds a considerable share, with Germany, France, and the UK as major markets.

Competitive Landscape and End-User Context

The 12 named players include Abbott Laboratories, Artivion, Boston Scientific, Edwards Lifesciences, JenaValve Technology, Johnson & Johnson MedTech, LivaNova, Medtronic, Meril Life Sciences, MicroPort Scientific, Peijia Medical, and Venus Medtech. By end user, hospitals held approximately 68.70% share in 2025, while specialized cardiac centers are expected to have the highest CAGR. Recent device approvals and launches show competition centered on transcatheter innovation, and the report also points to the rising U.S. population aged 65 and above as a long-term demand factor.

Technology and Clinical Programs

Technology and program development continue to broaden access. In March 2026, Medtronic reported that its AI-powered clinician alerts helped diagnose heart valve conditions and enabled timely interventions, linking detection to treatment. Historical data in the report covers 2021–2024, and the forecast extends to 2034, giving stakeholders a long horizon for planning investment in transcatheter devices, imaging, and training.

Challenges and Strategic Outlook

High procedure and device costs limit adoption in price-sensitive markets, partly because of limited reimbursement programs. AI-based imaging tools are identified as an opportunity, since they can improve procedural accuracy and device selection. With an 8.72% CAGR through 2034, manufacturers that expand transcatheter portfolios beyond aortic procedures, invest in imaging support, and address reimbursement and cost barriers are well positioned in the structural heart procedures market.

More Trending Latest Reports By Polaris Market Research:

microgreens-market

top-20-companies-in-printed-circuit-board-market-to-know-in-2025

europe-laundry-detergent-market

us-protein-bar-market

blockchain-technology-market

anti-drone-market

palm-oil-market

heat-treating-market

hot-melt-adhesives-market